KeyBanc Remains a Buy on ICU Medical (ICUI)
In a report released yesterday, Brett Fishbin from KeyBanc maintained a Buy rating on ICU Medical, with a price target of $175.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fishbin covers the Healthcare sector, focusing on stocks such as ICU Medical, Lemaitre Vascular, and Resmed. According to TipRanks, Fishbin has an average return of -5.3% and a 50.00% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ICU Medical with a $173.50 average price target.
Based on ICU Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $536.99 million and a GAAP net loss of $3.4 million. In comparison, last year the company earned a revenue of $589.13 million and had a GAAP net loss of $32.98 million
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICUI in relation to earlier this year. Most recently, in November 2025, Elisha Finney, a Director at ICUI sold 1,285.00 shares for a total of $180,439.70.
